The post-marketing safety of Esketamine among older adults(≥ 65): an real-world pharmacovigilance study.
BMC pharmacology & toxicology August 29, 2025 Bin Deng, Zhiwen Fu, Linjie Li et al. 3 citations
Older adults (65 years or older) treated with esketamine experience a higher risk of severe psychiatric and general adverse events compared to younger adults. Analysis of FDA Adverse Event Reporting System data from 2019 to 2024, covering 536 reports from older adults and 3,566 from younger adults, found that older adults had a higher incidence of dissociation, suicidal ideation, depression, and anxiety. They also reported more general and administration site conditions, indicating greater susceptibility to systemic and local reactions. Gastrointestinal and respiratory disorders were less frequent in older adults, but their potential impact remains critical. These findings highlight the need for careful patient selection, monitoring, and tailored treatment protocols for older adults receiving esketamine.